[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GUALTIERO PALARETI\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100226021","start-register-survey-on-anticoagulated-patients-register-100226021",false,"NCT02219984","START-Register: Survey on Anticoagulated Patients Register","Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment","Inclusion Criteria:\n\n* age \\>= 18 years\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* not willing to sign informed consent","ALL","18 Years",{"count":19,"type":20},15410,"ESTIMATED","1 Year","OBSERVATIONAL","This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs). The Registry is designed solely for observational purposes and is not intended to have any influence on the treatment of the single patients included.\n\nPatients are included when they start the anticoagulant treatment, whatever the drug used, or when they shift from a vitamin K antagonist (VKA) drug to one of the novel direct oral anticoagulants, provided that the therapy is expected to last at least 3 months.\n\nThe general aims of the study are to provide a better evaluation of efficacy and safety of different treatment options, and to improve our understanding of the risks\u002Fbenefits of the various anticoagulant drugs and the different therapy options.\n\nThe Registry is open to the participation of clinical centres or individual professionals (now called Participants) that are involved with management of anticoagulated patients.",[25,26,27],"Atrial Fibrillation","Venous Thromboembolism","Heart Valve Diseases or Prosthesis",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Anticoagulation","vitamin K antagonists","Warfarin","low molecular weight heparin","fondaparinux","antithrombotics","Direct oral anticoagulants","dabigatran","rivaroxaban","apixaban","edoxaban","atrial fibrillation","venous thromboembolism","RECRUITING","2023-02-01",{"date":45,"type":46},"2023-02-02","ACTUAL",{"date":48,"type":46},"2011-10",{"date":50,"type":20},"2027-11",{"name":52,"class":53},"GUALTIERO PALARETI","OTHER",""]